While treatment with palmitoylation inhibitors reduced the presence of palmitoylated APP in lipid rafts as well as the Aβ aggregate production, thus suggesting a role of palmitoylation in AD disease pathogenesis (Bhattacharyya et al., 2016). Here, APP is linked to Alzheimer disease.